Investigational Drug Information for Navitoclax
✉ Email this page to a colleague
What is the drug development status for Navitoclax?
Navitoclax is an investigational drug.
There have been 30 clinical trials for Navitoclax.
The most recent clinical trial was a Phase 2 trial, which was initiated on August 31st 2020.
The most common disease conditions in clinical trials are Leukemia, Lymphoid, Leukemia, and Neoplasms. The leading clinical trial sponsors are AbbVie, National Cancer Institute (NCI), and Genentech, Inc.
There are four hundred and sixteen US patents protecting this investigational drug and zero international patents.
Summary for Navitoclax
| US Patents | 416 |
| International Patents | 4,533 |
| US Patent Applications | 1,342 |
| WIPO Patent Applications | 857 |
| Japanese Patent Applications | 336 |
| Clinical Trial Progress | Phase 2 (2020-08-31) |
| Vendors | 61 |
Recent Clinical Trials for Navitoclax
| Title | Sponsor | Phase |
|---|---|---|
| Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia | Medical College of Wisconsin | Phase 1 |
| HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies | Fight Kids Cancer | Phase 1/Phase 2 |
| HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies | IBFM | Phase 1/Phase 2 |
Clinical Trial Summary for Navitoclax
Top disease conditions for Navitoclax
Top clinical trial sponsors for Navitoclax
US Patents for Navitoclax
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Navitoclax | ⤷ Sign Up | Pyrazol-3-ones that activate pro-apoptotic BAX | Dana-Farber Cancer Institute, Inc. (Boston, MA) | ⤷ Sign Up |
| Navitoclax | ⤷ Sign Up | Small molecules for the modulation of MCL-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders | Dana-Farber Cancer Institute, Inc. (Boston, MA) | ⤷ Sign Up |
| Navitoclax | ⤷ Sign Up | Methods for sensitizing a quiescent cancer stem cell to a BCR-ABL inhibitor | The Regents of the University of California (Oakland, CA) | ⤷ Sign Up |
| Navitoclax | ⤷ Sign Up | Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines | Signal Pharmaceuticals, LLC (San Diego, CA) | ⤷ Sign Up |
| Navitoclax | ⤷ Sign Up | Precise delivery of therapeutic agents to cell mitochondria for anti-cancer therapy | University of Georgia Research Foundation Inc. (Athens, GA) | ⤷ Sign Up |
| Navitoclax | ⤷ Sign Up | Substituted indole Mcl-1 inhibitors | Vanderbilt University (Nashville, TN) | ⤷ Sign Up |
| Navitoclax | ⤷ Sign Up | Antibody drug conjugates | Novartis AG (Basel, CH) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Navitoclax
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Navitoclax | Australia | AU2012322660 | 2031-10-11 | ⤷ Sign Up |
| Navitoclax | Australia | AU2017228527 | 2031-10-11 | ⤷ Sign Up |
| Navitoclax | Canada | CA2851788 | 2031-10-11 | ⤷ Sign Up |
| Navitoclax | Canada | CA3173988 | 2031-10-11 | ⤷ Sign Up |
| Navitoclax | European Patent Office | EP2766355 | 2031-10-11 | ⤷ Sign Up |
| Navitoclax | European Patent Office | EP3799871 | 2031-10-11 | ⤷ Sign Up |
| Navitoclax | World Intellectual Property Organization (WIPO) | WO2013055949 | 2031-10-11 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
